Coromed-Smo Kft.
- Address
- lock Available on a paid plan
Coromed-Smo Kft. - Cardiovascular & Metabolic Research Center
Coromed-Smo Kft. is a specialized clinical research center with extensive expertise in cardiovascular diseases and metabolic disorders. The center focuses on evaluating novel therapeutic approaches for heart failure, hypertension, and lipid disorders, participating in pivotal Phase III clinical trials that advance treatment options for patients with complex cardiovascular conditions.
- Heart failure research across the spectrum of ejection fraction types (HFpEF, HFmrEF, HFrEF), including prevention and post-myocardial infarction management
- Hypertension management studies, including uncontrolled and resistant hypertension treatment with novel aldosterone synthase inhibitors
- Advanced lipid disorder investigations, particularly severe hypertriglyceridemia, elevated lipoprotein(a), and atherosclerotic cardiovascular disease prevention
- Combination therapy trials integrating SGLT2 inhibitors with innovative cardiovascular medications
The center demonstrates particular strength in evaluating cardio-renal-metabolic therapeutics, including studies examining the intersection of heart failure with kidney dysfunction and obesity. Their research portfolio encompasses cutting-edge interventions such as RNA-based therapies, soluble guanylate cyclase stimulators, and novel agents targeting cardiovascular risk reduction and metabolic control in high-risk patient populations.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 2 therapeutic areas and 15 of 20 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 6 by active trials.
- 1AstraZeneca AB3active
lock +5 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1AstraZeneca AB5trials
lock +6 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 332 other sites in Hungary
Therapeutic Area Benchmark — Hungary
Select a therapeutic area to compare against other sites in Hungary.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Hungary
Market Share
Country: Hungary
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Coromed-Smo Kft.
lock Showing 1 of 26 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Impactof Maridebart Cafraglutide on Cardiovascular Outcomes in Participants with Atherosclerotic Cardiovascular Disease and Overweight or Obesity (MARITIME-CV) | Amgen Inc. | Phase III | Recruiting | Oct 2025 | — |
IMP list
lock Showing 1 of 20 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Bi 690517 | 3 | Unknown | 2024-10-18 | 2025-10-15 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.